Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. for $1.4 billion.
Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. for $1.4 billion on January 22, 2024. Immediately prior to the closing of the merger, all non-101 assets and liabilities,...
Source: marketscreener.com